R

RLS Radiopharmacies

Compounds and dispenses FDA-approved radiopharmaceuticals

Overview

RLS Radiopharmacies provides predictive and diagnostic radiopharmaceutical products and services for molecular imaging, serving hospitals, outpatient clinics, and mobile imaging units within a 100-mile radius. They compound and dispense FDA-approved radiopharmaceuticals using Nuclear Pharmacists and Radiation Safety Officers, with real-time tracking and secure sample access to ensure patient safety. They differentiate themselves as the only nationwide radiopharmacy network with The Joint Commission Gold Seal of Approval, combining local service with standardized, high-quality processes. Their goal is to expand clean room capabilities and double the network size by 2023 to reach more patients and extend service offerings.

Work here?Claim your company

About RLS Radiopharmacies

Simplify's Rating
Why RLS Radiopharmacies is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

BiotechnologyHealthcare

Company Size

201-500

Company Stage

N/A

Total Funding

N/A

Headquarters

Lake Zurich, IL

Founded

2020

Get referred to RLS Radiopharmacies

See people who can refer or advise you

Simplify Jobs

Simplify's take

What believers are saying

  • Telix said RLS drove $238 million revenue in 2025 and full-year 2026 contribution.
  • Q3 2026 installed the first IBA alpha-beam cyclotron at RLS Trevose near Philadelphia.
  • Eckert Ziegler generators equip all 31 sites for Ga-68 production and faster PET access.

What critics are saying

  • Telix's ITM merger consumes management attention and defers RLS-focused execution through December 2026.
  • RLS now depends on Telix volumes; any Illuccix or Gozellix share loss hits pharmacy utilization.
  • Nuclear medicine regulation, isotope supply, or cyclotron failure can strand invested capacity and kill expansion.

What makes RLS Radiopharmacies unique

  • Telix owns RLS; 31 Joint Commission-accredited radiopharmacies span nationwide last-mile radiopharmaceutical distribution.
  • RLS supplies PET, SPECT, and therapeutics from localized pharmacies within 100-mile service radii.
  • Trevose cyclotron deployment makes RLS a production platform, not just a distributor.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Flexible Work Hours
  • Professional Development Budget
  • Training Programs

Growth & Insights and Company News

6 month growth

2%

1 year growth

3%

2 year growth

3%
Contract Pharma
Sep 24th, 2024
Telix Acquires RLS

Expands its North American radiopharmacy network.

MarketScreener
Sep 22nd, 2024
Telix Pharmaceuticals Limited agreed to acquire RLS Inc. from Rls Group Ltd for $250 million.

Telix Pharmaceuticals Limited (ASX:TLX) agreed to acquire RLS (USA) Inc. from Rls Group Ltd for $250 million on September 23, 2024.

GlobeNewswire
Sep 22nd, 2024
Telix Acquires RLS to Expand Operations

Telix Pharmaceuticals Limited (ASX: TLX) announced the acquisition of RLS (USA) Inc. from RLS Group Ltd. This move expands Telix’s North American manufacturing and distribution capabilities, leveraging RLS’ 31 radiopharmacies and 100,000 sq ft of expansion space. The acquisition supports Telix’s strategy for a vertically integrated supply chain and enhances its radiometal production network, improving supply chain resilience and patient access across the U.S.

Business Wire
Apr 4th, 2024
Rls Radiopharmacies Partners With Eckert & Ziegler To Expand Production Of Gallium-68-Based Radiopharmaceuticals

LAKE MARY, Fla. & BERLIN--(BUSINESS WIRE)--RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network, today announced it has expanded its radiopharmaceutical contract development and manufacturing (rCDMO) capabilities by entering into a strategic agreement with global isotope technology leader Eckert & Ziegler (ISIN DE0005659700, SDAX). Under the partnership, all 31 of RLS’s radiopharmacies will be equipped with Eckert & Ziegler’s advanced GalliaPharm® generators, which the radiopharmacy network will utilize to produce high-quality, life-enhancing Gallium-68-based (Ga-68) radiopharmaceuticals. Ga-68 is crucial for Positron Emission Tomography (PET) imaging and plays a pivotal role in the accurate diagnosis and subsequent treatment planning for patients with neuroendocrine tumors and prostate cancer.“To help meet the ever-increasing demand for precision diagnostics in cancer treatment, we are collaborating with Eckert & Ziegler to place advanced Ga-68 radiolabeling technology into the hands of all our skilled radiopharmacists nationwide," said RLS CEO Stephen Belcher. “A powerful diagnostic isotope, Gallium has an extremely short half-life, necessitating the need for Ga-68-based radiopharmaceuticals to be produced within minutes of patient dosing. By bringing Eckert & Ziegler’s GalliaPharm® generators into our network, we are closing the patient care gap in many parts of the U.S

Business Wire
Apr 4th, 2024
Rls Radiopharmacies Partners With Eckert Ziegler To Expand Production Of Gallium-68-Based Radiopharmaceuticals

LAKE MARY, Fla. & BERLIN--(BUSINESS WIRE)--RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network, today announced it has expanded its radiopharmaceutical contract development and manufacturing (rCDMO) capabilities by entering into a strategic agreement with global isotope technology leader Eckert & Ziegler (ISIN DE0005659700, SDAX). Under the partnership, all 31 of RLS’s radiopharmacies will be equipped with Eckert & Ziegler’s advanced GalliaPharm® generators, which the radiopharmacy network will utilize to produce high-quality, life-enhancing Gallium-68-based (Ga-68) radiopharmaceuticals. Ga-68 is crucial for Positron Emission Tomography (PET) imaging and plays a pivotal role in the accurate diagnosis and subsequent treatment planning for patients with neuroendocrine tumors and prostate cancer.“To help meet the ever-increasing demand for precision diagnostics in cancer treatment, we are collaborating with Eckert & Ziegler to place advanced Ga-68 radiolabeling technology into the hands of all our skilled radiopharmacists nationwide," said RLS CEO Stephen Belcher. “A powerful diagnostic isotope, Gallium has an extremely short half-life, necessitating the need for Ga-68-based radiopharmaceuticals to be produced within minutes of patient dosing. By bringing Eckert & Ziegler’s GalliaPharm® generators into our network, we are closing the patient care gap in many parts of the U.S

Recently Posted Jobs

Sign up to get curated job recommendations

RLS Radiopharmacies is Hiring for 27 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs